BMRN - Company ID 0001048477
The table below shows BIOMARIN PHARMACEUTICAL INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.02B | $989.71M | $766.21M | $776.13M | $825.41M | $745.14M |
| Cost of revenue | $205.42M | $202.79M | $195.00M | $140.09M | $150.09M | $151.56M |
| Gross profit | - | - | - | - | - | - |
| R&D | - | $206.95M | $178.80M | $409.48M | $161.31M | $158.73M |
BIOMARIN PHARMACEUTICAL INC reported annual revenue of $3.22B for fiscal year 2025. That is up 12.9% from $2.85B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.12B (FY 2016) to $3.22B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $333.64M | $395.55M | $258.29M | $268.42M | $232.28M | $206.12M |
| Operating income | -$82.08M | $110.92M | $129.64M | -$46.69M | $276.89M | $223.89M |
| Income tax | -$8.94M | $16.62M | $35.68M | $4.42M | $57.34M | $52.40M |
| Net income | -$122.83M | $44.76M | $105.53M | -$30.74M | $240.53M | $185.69M |
| EPS (diluted) | -$0.63 | $0.23 | $0.54 | -$0.16 | $1.23 | $0.95 |